A number of catalysts could drive gains for Teladoc Health in the coming months, according to Goldman Sachs.
Analyst David Roman initiated coverage on the name with a buy rating, and his price target of $14 implies 56.3% upside from Thursday's close.
Looking ahead to next year, he anticipates that the virtual health care company's results will be driven by slightly better-than-expected top-line growth in its Integrated Care segment.
But that didn't quite come to fruition as the pandemic eased with patients returning to in-person visits and larger health care players developing their own telehealth solutions.
Among the 27 analysts covering it, only six in total have a strong buy or buy rating.
Persons:
Goldman Sachs, David Roman, Roman
Organizations:
Teladoc Health